Mark Miller - Biomerieux Ex Affairs
| BIM Stock | EUR 117.10 0.20 0.17% |
Insider
Mark Miller is Ex Affairs of Biomerieux SA
| Phone | 33 4 78 87 20 00 |
| Web | https://www.biomerieux.com |
Mark Miller Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mark Miller against Biomerieux stock is an integral part of due diligence when investing in Biomerieux. Mark Miller insider activity provides valuable insight into whether Biomerieux is net buyers or sellers over its current business cycle. Note, Biomerieux insiders must abide by specific rules, including filing SEC forms every time they buy or sell Biomerieux'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mark Miller over a month ago Acquisition by Mark Miller of 80000 shares of Goosehead Insurance at 115.72 subject to Rule 16b-3 | ||
Mark Miller over a month ago Disposition of 34 shares by Mark Miller of ViaSat at 7.4 subject to Rule 16b-3 | ||
Mark Miller over two months ago Disposition of 58327 shares by Mark Miller of Goosehead Insurance at 10.0 subject to Rule 16b-3 | ||
Mark Miller over six months ago Acquisition by Mark Miller of 5000 shares of Goosehead Insurance at 57.99 subject to Rule 16b-3 |
Biomerieux Management Efficiency
The company has return on total asset (ROA) of 0.1008 % which means that it generated a profit of $0.1008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1751 %, meaning that it generated $0.1751 on every $100 dollars invested by stockholders. Biomerieux's management efficiency ratios could be used to measure how well Biomerieux manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MarieLaurence Bouchon | Edenred SA | 48 | |
| Yvoine Remy | Eurofins Scientific SE | N/A | |
| Olivier Guitard | Sartorius Stedim Biotech | N/A | |
| Patrick Rouvillois | Edenred SA | 51 | |
| Stephan Gagne | Ipsen SA | N/A | |
| Laurent Lebras | Eurofins Scientific SE | N/A | |
| Yannis Tourcomanis | Teleperformance SE | N/A | |
| Daniel Julien | Teleperformance SE | 71 | |
| Petra Kirchhoff | Sartorius Stedim Biotech | 54 | |
| Agustin Grisanti | Teleperformance SE | 50 | |
| Yan MD | Ipsen SA | 56 | |
| Leigh Ryan | Teleperformance SE | 70 | |
| Virginie Heuz | Teleperformance SE | N/A | |
| Steven Hildemann | Ipsen SA | N/A | |
| David Bryant | Eurofins Scientific SE | N/A | |
| Gilles Martin | Eurofins Scientific SE | 60 | |
| Heiko Imhl | Sartorius Stedim Biotech | N/A | |
| Quy NguyenNgoc | Teleperformance SE | 54 | |
| Benedikt Orzelek | Sartorius Stedim Biotech | N/A | |
| Gwenan White | Ipsen SA | N/A | |
| John Mackay | Sartorius Stedim Biotech | 61 | |
Management Performance
Biomerieux SA Leadership Team
Elected by the shareholders, the Biomerieux's board of directors comprises two types of representatives: Biomerieux inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biomerieux. The board's role is to monitor Biomerieux's management team and ensure that shareholders' interests are well served. Biomerieux's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biomerieux's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frederic Beseme, Head CSR | ||
| Guillaume Bouhours, Ex CFO | ||
| Pierre Boulud, Chief Operations | ||
| Franois Lacoste, Ex RD | ||
| Mark Miller, Ex Affairs | ||
| Alexandre Merieux, Chairman CEO | ||
| Valerie Leylde, Communications HR | ||
| Sylvain Morgeau, Investor Relations | ||
| Pierre Charbonnier, Manufacturing Quality | ||
| Yasha Mitrotti, Ex Microbiology |
Biomerieux Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biomerieux a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | |||
| Return On Asset | 0.1 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.21 % | |||
| Current Valuation | 11.4 B | |||
| Shares Outstanding | 118.37 M | |||
| Shares Owned By Insiders | 64.28 % | |||
| Shares Owned By Institutions | 18.57 % | |||
| Price To Earning | 35.41 X | |||
| Price To Book | 3.27 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Biomerieux Stock
Biomerieux financial ratios help investors to determine whether Biomerieux Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biomerieux with respect to the benefits of owning Biomerieux security.